Foghorn Therapeutics Long Term Debt

As of the most recent data (March 2026), FHTX shows a long-term debt of $40M. That compares with $26M in the prior-year period — up 55.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FHTX's long-term debt is now $40M (was $26M) — a 55.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Foghorn Therapeutics is outperforming or lagging.

Tracking FHTX's long-term debt over time shows whether Foghorn Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $40M That compares with $26M in the prior-year period — up 55.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Foghorn Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $40M) with ownership activity and broader fundamentals.

Foghorn Therapeutics's long-term debt is $40M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.